Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
Conditions
Brief summary
This phase I trial studies the side effects and best dose of fludarabine (fludarabine phosphate) when given together with iodine I 131 tositumomab in treating older patients who are undergoing an autologous or syngeneic stem cell transplant for relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL). Radiolabeled monoclonal antibodies, such as iodine I 131 tositumomab, can find cancer cells and carry cancer-killing substances to them without harming normal cells. Drugs used in chemotherapy, such as fludarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. A peripheral stem cell transplant may be able to replace blood-forming cells that were destroyed by chemotherapy and radiation therapy. Giving iodine I 131 tositumomab together with fludarabine followed by autologous stem cell transplant may be an effective treatment for NHL
Detailed description
PRIMARY OBJECTIVES: I. To estimate the maximally tolerated dose of fludarabine that can be combined with 131I-anti-CD20 (iodine I 131 tositumomab) delivering =\< 27Gy to critical normal organs followed by autologous or syngeneic transplantation in patients \>= 60 years of age with relapsed B-NHL. SECONDARY OBJECTIVES: I. To assess the overall and progression-free survival of the above regimen in such patients. II. To evaluate the response rates of the above therapy. III. To evaluate the toxicity and tolerability of the above therapy. IV. To evaluate the feasibility of delivering concurrent high-dose radioimmunotherapy (RIT) and chemotherapy. OUTLINE: This is a dose-escalation study of fludarabine phosphate as used in combination with I 131 tositumomab and stem cell transplant. Patients receive a dosimetric dose of iodine I 131 tositumomab intravenously (IV) over 40-60 minutes on day -24 followed by gamma camera imaging over the next 6 days. Patients then receive a therapeutic dose of iodine I 131 tositumomab via central line over 40-60 minutes on day -14. Patients also receive fludarabine phosphate IV once daily (QD) on days -11 to -9 OR days -11 or -7. Patients undergo autologous or syngeneic peripheral blood stem cell transplantation on day 0. Patients with circulating lymphoma cells by peripheral smear receive tositumomab IV over 1 hour OR rituximab IV over 1 hour followed by tositumomab IV over 1 hour before the dosimetric iodine I 131 tositumomab infusion. After completion of study treatment, patients are followed up at 1, 3, 6, and 12 months and then annually thereafter.
Interventions
DRUGfludarabine phosphate
Given IV
PROCEDUREperipheral blood stem cell transplantation
Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
RADIATIONiodine I 131 tositumomab
Given IV (dosimetric dose) or via central line (therapeutic dose)
OTHERlaboratory biomarker analysis
Correlative studies
OTHERflow cytometry
Correlative studies
GENETICpolymerase chain reaction
Correlative studies
Sponsors
National Cancer Institute (NCI)
Fred Hutchinson Cancer Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have a histologically confirmed diagnosis of lymphoma expressing the CD20 antigen and generally must have failed at least one prior standard systemic therapy; the exception will be mantle cell lymphoma (MCL) patients, who may be enrolled while in first complete remission (CR) in accordance with current transplant standard of care for these patients * Creatinine (Cr) \< 2.0 * Bilirubin \< 1.5 mg/dL, with the exception of patients thought to have Gilbert's syndrome, whom may have a total bilirubin above 1.5 mg/dL * All patients eligible for therapeutic study must have (\>= 2x10\^6 CD34/kg) autologous hematopoietic stem cells harvested and cryopreserved, or this number of cells harvested from a syngeneic donor * Patients must have an expected survival of \> 60 days and must be free of major infection * DONOR: Syngeneic donors must be confirmed syngeneic by ABO typing, human leukocyte antigen (HLA) typing, and variable number tandem repeat (VNTR) analysis * DONOR: Syngeneic donors must meet eligibility under Standard Practice Guidelines/Standard Treatment
Exclusion criteria
* Circulating anti-mouse antibody (HAMA) (to be determined before both dosimetry and therapy) * Systemic anti-lymphoma therapy given in the previous 30 days before the scheduled therapy dose * Inability to understand or give an informed consent * Prior radiation \> 20 Gy to any critical normal organ (e.g., lung, liver, spinal cord, \> 25% of red marrow) * Central nervous system lymphoma * Other serious medical conditions considered to represent contraindications to bone marrow transplant (BMT) (e.g., abnormally decreased cardiac ejection fraction, diffusing capacity (DLCO) \< 50% predicted, patient on supplemental oxygen, acquired Immunodeficiency syndrome \[AIDS\], etc.) * Pregnancy * Prior bone marrow or stem cell transplant * South West Oncology Group (SWOG) performance status \>= 2 * Unable to perform self-care during radiation isolation * Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma/well differentiated lymphocytic lymphoma
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose/dose limiting toxicity | Up to 30 days post-transplant | Assessed according to Bearman scale for Regimen-Related Toxicities. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall and progression-free survival rate | Up to 6 years | — |
| Response rate | Up to 12 months | — |
| Toxicity/tolerability of study regimen | Through day 100 post-transplant | Type, frequency, and severity of adverse events grade 3 and above (assessed by National Cancer Institute (NCI) common terminology criteria for adverse events (CTCAE) v3.0. |
| Feasibility of concurrent high-dose radioimmunotherapy and chemotherapy | Through day -7 prior to transplant | Ability to administer complete course of I 131-tositumomab and fludarabine phosphate as descried in protocol. |
Countries
United States
Outcome results
None listed